WHO nod for Covaxin expected in July-September period: Bharat Biotech

Company says regulatory approvals for Covaxin are also in process in more than 60 countries, including the US, Brazil, Hungary

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Sohini Das Mumbai
2 min read Last Updated : May 26 2021 | 12:28 AM IST
Amid fears that Indians who have been vaccinated with indigenously developed Covid-19 shot Covaxin might find it difficult to travel abroad until the WHO puts it in EUL, Bharat Biotech said on Tuesday that it expects the regulatory approvals from WHO by July-September.

The company said that an application for full emergency use listing (EUL) has been submitted to the World Health Organization (WHO), Geneva and the regulatory approvals are expected within July to September.

Bharat Biotech added that regulatory approvals for Covaxin are in process in more than 60 countries, including the US, Brazil, Hungary etc.

"Emergency use authorisations have been obtained in 13 countries with more to follow," the Hyderabad based vaccine maker claimed.

Allaying fears of students and travellers, the company also went on to add that most countries recommend vaccinations against Covid-19. "Unvaccinated travelers can travel with negative RT-PCR tests prior to travel, in the absence of any other country specific travel restrictions," Bharat Biotech said.

Reports suggest that the global vaccine collaboration Covax, which is led by WHO, Gavi has asked the WHO to expedite the approval for Covaxin. This has been done to expand the basket of Covid19 vaccines available with Covax. 

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusBharat BiotechCoronavirus Vaccine

First Published: May 25 2021 | 7:34 PM IST

Next Story